Correction to Consolidated Interim Report 1 January – 30 June 202614 August 2026Announcement no. 10 The previous announcement with the half year report was missing the report. The announcement is re-published, including the report. On 14 August 2026, the Board of Directors and the Executive Board of Pharma Equity Group A/S (“PEG”, “The Company” or the “Group”) considered and approved the interim report for the Group for the period 1 January – 30 June 2026 (“H1 2026 report”), which can be summarized as follows: The headlines for the period can be summarized as followsReponex Pharmaceuticals A/S strengthened its patent position with a new European patent covering the treatment of inflammatory bowel disease, including pouchitis The patent application relating to the treatment regime for RNX-051...

Consolidated Interim Report 1 January – 30 June 202614 August 2025Announcement no. 9 On 14 August 2026, the Board of Directors and the Executive Board of Pharma Equity Group A/S (“PEG”, “The Company” or the “Group”) considered and approved the interim report for the Group for the period 1 January – 30 June 2026 (“H1 2026 report”), which can be summarized as follows: The headlines for the period can be summarized as followsReponex Pharmaceuticals A/S strengthened its patent position with a new European patent covering the treatment of inflammatory bowel disease, including pouchitis The patent application relating to the treatment regime for RNX-051 has entered the national phase in several key markets, including Europe, the USA, Japan, China and India An arbitral award confirmed that PEG...

The Board of Director of Tivoli A/S has adopted the interim report for the period 1 January – 30 June 2026 on 14 August 2026.   Results for the period 1 January – 30 June 2026 in outline: A revenue of DKK of 470.3 million compared to DKK 445.0 million last year (+6%).  An EBITDA of DKK -38.3 million compared to DKK -17.8 million last year.  A profit before tax of DKK -100.9 million compared to DKK -76.1 million last year.  1,321,000 visitors compared to 1,325,000 last year. Tivoli delivered growth in both revenue and spend per guest during the first half of the year, driven by increased consumption across the Gardens’ wide range of attractions, cultural offerings and restaurants. Visitor numbers remained on par with last year despite challenging weather conditions, particularly in June, which was characterised by highly variable weather,...

Due to a technical error the attachment of the interim report was missing on Oslo Børs. It is hereby attached. — Today, Schouw & Co. released its interim report for the second quarter of 2026; Schouw & Co. delivered a strong performance in Q2 2026, with higher activity levels, productivity improvements, and operational optimisation initiatives supporting significant earnings growth. HighlightsDKK 9.0bn revenue – a 5% increase DKK 828m EBITDA – a 17% increase 47.3k tonnes Scope 1+2 CO2e emissions – a 12% reduction DKK 410m cash flow from operations – a 24% decrease DKK 14.19 earnings per share – a 39% improvement 14.1% ROIC excluding goodwill – a 1.6 pp improvement Full-year revenue and EBITDA guidance raised.Statement by Jens Bjerg Sørensen, President of Schouw & Co.– Schouw & Co. delivered a strong Q2 2026...

Today, Schouw & Co. released its interim report for the second quarter of 2026; Schouw & Co. delivered a strong performance in Q2 2026, with higher activity levels, productivity improvements, and operational optimisation initiatives supporting significant earnings growth. HighlightsDKK 9.0bn revenue – a 5% increase DKK 828m EBITDA – a 17% increase 47.3k tonnes Scope 1+2 CO2e emissions – a 12% reduction DKK 410m cash flow from operations – a 24% decrease DKK 14.19 earnings per share – a 39% improvement 14.1% ROIC excluding goodwill – a 1.6 pp improvement Full-year revenue and EBITDA guidance raised.Statement by Jens Bjerg Sørensen, President of Schouw & Co.– Schouw & Co. delivered a strong Q2 2026 performance, with earnings growth driven by higher activity levels, operational improvements, and continued productivity...

07:00 London, 09:00 Helsinki, 14 August 2026 – Afarak Group SE (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2026    H1/26 H1/25 2025Revenue EUR million 57.1 77.1 141.3EBITDA EUR million 1.6 6.9 -0.2EBIT EUR million 0.5 5.9 -2.6Earnings before taxes EUR million 0.1 3.4 -7.5(Loss) / Profit for the period EUR million -0.7 2.4 -8.9Earnings per share EUR 0.00 0.01 -0.03EBITDA margin   2.8% 9.0% -0.2EBIT margin   0.8% 7.7% -1.8Earnings margin   0.2% 4.5% -5.3Personnel (end of period)   625 613 626FIRST HALF 2026 HIGHLIGHTSThe Group recorded an improved performance during H1 2026 compared with H2 2025; Revenue decreased by 25.9% to EUR 57.1 (H1/2025: 77.1) million; Processed material sold decreased by 25.9% to 11,372 (H1/2025: 15,354) tonnes; Tonnage...